Soleno Therapeutics, Inc.
$52.67
▲
6.76%
2026-04-21 09:28:01
soleno.life
NCM: SLNO
Explore Soleno Therapeutics, Inc. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$2.72 B
Current Price
$52.67
52W High / Low
$90.32 / $29.43
Stock P/E
130.16
Book Value
$8.61
Dividend Yield
—
ROCE
2.98%
ROE
6.01%
Face Value
—
EPS
$0.39
Exp Qtr EPS
—
Sector
Healthcare
Industry
Biotechnology
Employees
182
Beta
-2.81
Debt / Equity
11.68
Current Ratio
5.8
Quick Ratio
5.55
Forward P/E
-23.19
Price / Sales
14.3
Enterprise Value
$2.46 B
EV / EBITDA
145.23
EV / Revenue
12.94
Rating
Hold
Target Price
$60.12
EPS Forecast (FY)
—
Pros
- Balance sheet leverage appears manageable.
- Short-term liquidity looks comfortable.
- Strong operating margin profile.
- Net margin remains healthy.
Cons
- Return on equity is on the weaker side.
- Capital efficiency is modest.
- Valuation is rich on a P/E basis.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | Cardio Diagnostics Holdings, Inc. | $1.97 | — | $5.95 M | — | -90.54% | -78.62% | $17.4 / $0.97 | $3.82 |
| 2. | MetaVia Inc. | $1.51 | — | $7.13 M | — | -250.37% | -1.96% | $19.03 / $1.17 | $2.31 |
| 3. | Allarity Therapeutics, Inc. | $1.25 | — | $19.46 M | — | -148.49% | -1.04% | $2.35 / $0.77 | $0.61 |
| 4. | Terns Pharmaceuticals, Inc. | $52.74 | — | $6.09 B | — | -10.92% | -14.23% | $53.19 / $2.23 | $8.96 |
| 5. | Cibus, Inc. | $1.56 | — | $118.83 M | — | -23.41% | -2.21% | $4.19 / $1.09 | $0.4 |
| 6. | SeaStar Medical Holding Corporation | $4.63 | — | $16.77 M | — | -116.89% | -2.95% | $13.4 / $2.07 | $2.71 |
| 7. | Definium Therapeutics, Inc. | $23.18 | — | $2.26 B | — | -44.54% | -64.06% | $23.41 / $5.36 | $3.36 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | |
|---|---|---|---|---|---|---|
| Sales | 91.73 M | 66.02 M | 32.66 M | 0 M | 0 M | — |
| Operating Profit | 40.43 M | 22.72 M | -5.42 M | -42.78 M | -58.79 M | — |
| Net Profit | 43.36 M | 26.01 M | -4.71 M | -43.77 M | -55.98 M | — |
| EPS in Rs | 0.84 | 0.5 | -0.09 | -0.85 | -1.08 | -1.83 |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 190.41 M | 0 M | 0 M | 0 M |
| Operating Profit | 14.95 M | -184.43 M | -38.67 M | -25.11 M |
| Net Profit | 20.89 M | -175.85 M | -38.99 M | -24.07 M |
| EPS in Rs | 0.4 | -3.4 | -0.75 | -0.47 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 563.83 M | 330.97 M | 180.69 M | 26.5 M |
| Total Liabilities | 113.72 M | 85.86 M | 23.18 M | 16.15 M |
| Equity | 450.12 M | 245.11 M | 157.51 M | 10.35 M |
| Current Assets | 355.81 M | 293.89 M | 171.36 M | 15.65 M |
| Current Liabilities | 61.36 M | 18.75 M | 11.51 M | 7.31 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | 46.8 M | -69.1 M | -24.94 M | -20.78 M |
| Investing CF | -201.78 M | -225.68 M | 0 M | -0.01 M |
| Financing CF | 137.16 M | 213.03 M | 180.02 M | 14.09 M |
| Free CF | 46.73 M | -69.31 M | -24.94 M | -20.79 M |
| Capex | -0.07 M | -0.22 M | — | -0.01 M |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Revenue Growth % | — | — | — | — |
| Earnings Growth % | -351.04% | -62% | — | — |
| Profit Margin % | — | — | — | — |
| Operating Margin % | — | — | — | — |
| Gross Margin % | — | — | — | — |
| EBITDA Margin % | — | — | — | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
| Date | Split |
|---|---|
| 2022-08-26 | 1:0.0666667 |